Research progress on molecular mechanism of primary aldosteronism

doi:10.16138/j.1673-6087.2023.04.010

Abstract

CLC Number:

R586.24

JIANG Yiran, WANG Weiqing. Research progress on molecular mechanism of primary aldosteronism[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 261-265.

References 40

[1]	Choi M, Scholl UI, Yue P, et al. K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension[J]. Science, 2011, 331(6018): 768-772. doi: 10.1126/science.1198785 URL
[2]	Fernandes-Rosa FL, Williams TA, Riester A, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma[J]. Hypertension, 2014, 64(2): 354-361. doi: 10.1161/HYPERTENSIONAHA.114.03419 pmid: 24866132
[3]	Lenzini L, Rossitto G, Maiolino G, et al. A meta-analysis of somatic KCNJ5 K⁺ channel mutations in 1636 patients with an aldosterone-producing adenoma[J]. J Clin Endocrinol Metab, 2015, 100(8): E1089-E1095. doi: 10.1210/jc.2015-2149 URL
[4]	Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas[J]. J Clin Endocr-inol Metab, 2012, 97(4): 1311-1319.
[5]	Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma[J]. Hypertension, 2015, 65(3): 622-628. doi: 10.1161/HYPERTENSIONAHA.114.03346 URL
[6]	Cao Y, Zhou W, Li L, et al. Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types[J]. Cell Res, 2018, 28(5): 601-604. doi: 10.1038/s41422-018-0019-5 pmid: 29507395
[7]	De Sousa K, Boulkroun S, Baron S, et al. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma[J]. Hypertension, 2020, 75(4): 1034-1044. doi: 10.1161/HYPERTENSIONAHA.119.14177 pmid: 32114847
[8]	Zhang C, Wu L, Jiang L, et al. KCNJ5 mutation contributes to complete clinical success in aldosterone-producing adenoma[J]. Endocr Pract, 2021, 27(7): 736-742. doi: 10.1016/j.eprac.2021.01.007 pmid: 33678553
[9]	Geller DS, Zhang J, Wisgerhof MV, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism[J]. J Clin Endocrinol Metab, 2008, 93(8): 3117-3123. doi: 10.1210/jc.2008-0594 URL
[10]	Mulatero P, Monticone S, Rainey WE, et al. Role of KCNJ5 in familial and sporadic primary aldosteronism[J]. Nat Rev Endocrinol, 2013, 9(2): 104-112. doi: 10.1038/nrendo.2012.230 pmid: 23229280
[11]	Scholl UI, Abriola L, Zhang C, et al. Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma[J]. J Clin Invest, 2017, 127(7): 2739-2750. doi: 10.1172/JCI91733 pmid: 28604387
[12]	Maiolino G, Ceolotto G, Battistel M, et al. Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism[J]. Blood Press, 2018, 27(4): 200-205. doi: 10.1080/08037051.2018.1436961 URL
[13]	Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension[J]. Nat Genet, 2013, 45(9): 1055-1060. doi: 10.1038/ng.2716 pmid: 23913004
[14]	Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism[J]. Nat Genet, 2013, 45(9): 1050-1054. doi: 10.1038/ng.2695 pmid: 23913001
[15]	Nanba K, Omata K, Else T, et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans[J]. J Clin Endocrinol Metab, 2018, 103(10): 3869-3876. doi: 10.1210/jc.2018-01004 pmid: 30085035
[16]	Nanba K, Omata K, Gomez-Sanchez CE, et al. Genetic characteristics of aldosterone-producing adenomas in Blacks[J]. Hypertension, 2019, 73(4): 885-892. doi: 10.1161/HYPERTENSIONAHA.118.12070 pmid: 30739536
[17]	Pinggera A, Mackenroth L, Rump A, et al. New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy[J]. Hum Mol Genet, 2017, 26(15): 2923-2932. doi: 10.1093/hmg/ddx175 pmid: 28472301
[18]	Scholl UI, Stölting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism[J]. Elife, 2015, 4: e06315. doi: 10.7554/eLife.06315 URL
[19]	Daniil G, Fernandes-Rosa FL, Chemin J, et al. CACNA1H mutations are associated with different forms of primary aldosteronism[J]. EBioMedicine, 2016, 13: 225-236. doi: S2352-3964(16)30457-1 pmid: 27729216
[20]	Nanba K, Blinder AR, Rege J, et al. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma[J]. Hypertension, 2020, 75(3): 645-649. doi: 10.1161/HYPERTENSIONAHA.119.14349 URL
[21]	Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension[J]. Nat Genet, 2013, 45(4): 440-444. doi: 10.1038/ng.2550 pmid: 23416519
[22]	Tauber P, Aichinger B, Christ C, et al. Cellular pathophysiology of an adrenal adenoma-associated mutant of the plasma membrane Ca²⁺-ATPase ATP2B3[J]. ndocrinology, 2016, 157(6): 2489-2499.
[23]	Stowasser M, Gordon RD. Familial hyperaldosteronism[J]. J Steroid Biochem Mol Biol, 2001, 78(3): 215-229. doi: 10.1016/S0960-0760(01)00097-8 URL
[24]	Scholl UI, Stölting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type Ⅱ[J]. Nat Genet, 2018, 50(3): 349-354. doi: 10.1038/s41588-018-0048-5 pmid: 29403011
[25]	Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism[J]. Nat Genet, 2018, 50(3): 355-361. doi: 10.1038/s41588-018-0053-8 pmid: 29403012
[26]	Åkerström T, Maharjan R, Sven Willenberg H, et al. Activating mutations in CTNNB1 in aldosterone producing adenomas[J]. Sci Rep, 2016, 6: 19546. doi: 10.1038/srep19546 pmid: 26815163
[27]	Berthon A, Drelon C, Val P. Pregnancy, primary aldo-steronism, and somatic CTNNB1 mutations[J]. N Engl J Med, 2016, 374(15): 1493-1494.
[28]	Rhayem Y, Perez-Rivas LG, Dietz A, et al. PRKACA somatic mutations are rare findings in aldosterone-producing adenomas[J]. J Clin Endocrinol Metab, 2016, 101(8): 3010-3017. doi: 10.1210/jc.2016-1700 pmid: 27270477
[29]	Zilbermint M, Xekouki P, Faucz FR, et al. Primary aldosteronism and ARMC5 variants[J]. J Clin Endocrinol Metab, 2015, 100(6): E900-E999. doi: 10.1210/jc.2014-4167 URL
[30]	Mulatero P, Schiavi F, Williams TA, et al. ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions[J]. J Hum Hypertens, 2016, 30(6): 374-378. doi: 10.1038/jhh.2015.98 pmid: 26446392
[31]	Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical zonation in humans under normal and pathological conditions[J]. J Clin Endocrinol Metab, 2010, 95(5): 2296-2305. doi: 10.1210/jc.2009-2010 pmid: 20200334
[32]	Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands[J]. Proc Natl Acad Sci U S A, 2015, 112(33): E4591-E4599.
[33]	Nishimoto K, Koga M, Seki T, et al. Immunohistoche-mistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism[J]. Mol Cell Endocrinol, 2017, 441: 124-133. doi: S0303-7207(16)30422-1 pmid: 27751767
[34]	Fernandes-Rosa FL, Giscos-Douriez I, Amar L, et al. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma[J]. Hypertension, 2015, 66(5): 1014-1022. doi: 10.1161/HYPERTENSIONAHA.115.05993 pmid: 26351028
[35]	Davies LA, Hu C, Guagliardo NA, et al. TASK channel deletion in mice causes primary hyperaldosteronism[J]. Proc Natl Acad Sci U S A, 2008, 105(6): 2203-2208. doi: 10.1073/pnas.0712000105 URL
[36]	Guagliardo NA, Yao J, Hu C, et al. TASK-3 channel deletion in mice recapitulates low-renin essential hypertension[J]. Hypertension, 2012, 59(5): 999-1005. doi: 10.1161/HYPERTENSIONAHA.111.189662 pmid: 22493079
[37]	Penton D, Bandulik S, Schweda F, et al. Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension[J]. Endocrinology, 2012, 153(10): 4740-4748. pmid: 22878402
[38]	Seidel E, Schewe J, Zhang J, et al. Enhanced Ca²⁺ signaling, mild primary aldosteronism, and hypertension in a familial hyperaldosteronism mouse model (Cacna1h^M1560V/+)[J]. Proc Natl Acad Sci U S A, 2021, 118(17): e2014876118.
[39]	Schewe J, Seidel E, Forslund S, et al. Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation[J]. Nat Commun, 2019, 10(1): 5155. doi: 10.1038/s41467-019-13033-4 pmid: 31727896
[40]	Göppner C, Orozco IJ, Hoegg-Beiler MB, et al. Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism[J]. Nat Commun, 2019, 10(1): 4678. doi: 10.1038/s41467-019-12113-9 pmid: 31615979

Research progress on molecular mechanism of primary aldosteronism

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	KE Yuya, GONG Yanchun. Research progress of cardiovascular damage in primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 301-304.
[2]	LAI Liqin, GONG Yanchun. Research progress of chronic kidney injury in primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 211-214.